Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian K Roberts

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
The Journal of Clinical Endocrinology and Metabolism|July 15, 2011
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatinHarold E Bays, Sherwyn Schwartz, Thomas Littlejohn, et al.
Pituitary|February 3, 2007
Efficacy and safety of CyberKnife radiosurgery for acromegalyBrian K Roberts, Daniel L Ouyang, Shivanand P Lad, et al.
Pituitary|August 14, 2016
Efficacy and safety of CyberKnife radiosurgery for acromegalyBrian K Roberts, Daniel L Ouyang, Shivanand P Lad, et al.
Med (New York, N.Y.)|March 19, 2025
Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinismHuseyin Demirbilek, Maria Melikyan, Violeta Iotova, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 21, 2016
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKDRobert Provenzano, Anatole Besarab, Chao H Sun, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
The Journal of Clinical Endocrinology and Metabolism|July 15, 2011
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatinHarold E Bays, Sherwyn Schwartz, Thomas Littlejohn, et al.
Pituitary|February 3, 2007
Efficacy and safety of CyberKnife radiosurgery for acromegalyBrian K Roberts, Daniel L Ouyang, Shivanand P Lad, et al.
Pituitary|August 14, 2016
Efficacy and safety of CyberKnife radiosurgery for acromegalyBrian K Roberts, Daniel L Ouyang, Shivanand P Lad, et al.
Med (New York, N.Y.)|March 19, 2025
Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinismHuseyin Demirbilek, Maria Melikyan, Violeta Iotova, et al.
Clinical Journal of the American Society of Nephrology : CJASN|April 21, 2016
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKDRobert Provenzano, Anatole Besarab, Chao H Sun, et al.
Pageof 2